Insights into the genetic architecture of diabetic nephropathy

Current Diabetes Reports

Volumn 12, Issue 4, 2012, Pages 423-431

  Palmer, Nicholette D ^a   Freedman, Barry I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Albuminuria; Association; Genetics; Kidney; Nephropathy; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN L1 GENE; ARTICLE; DIABETIC NEPHROPATHY; EPIGENETICS; GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HISTORY; HUMAN; MOLECULAR PATHOLOGY; NON MUSCLE MYOSIN HEAVY CHAIN 9 GENE; NONHUMAN; PHENOTYPIC VARIATION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ALBUMINURIA; APOLIPOPROTEINS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EARLY DIAGNOSIS; FEMALE; GENETIC LINKAGE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LIPOPROTEINS, HDL; MALE; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS;

EID: 84865596035     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0279-2     Document Type: Article

References (80)

1. Perkins BA, Ficociello LH, Roshan B, Warram JH, Krolewski AS. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 77(1):57-64.
2. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348(23):2285-93. (Pubitemid 36638102)
3. Buckalew VM, Jr., Freedman BI. Effects of race on albuminuria and risk of cardiovascular and kidney disease. Expert Rev Cardiovasc Ther.9(2):245-9.
4. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320(18):1161-5. (Pubitemid 19124296)
5. Freedman BI, Spray BJ, Tuttle AB, Buckalew Jr VM. The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis. 1993;21(4):387-93. (Pubitemid 23132903)
6. Freedman BI, Volkova NV, Satko SG, Krisher J, Jurkovitz C, Soucie JM, et al. Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol. 2005;25(6):529-35. (Pubitemid 41816046)
7. Quinn M, Angelico MC, Warram JH, Krolewski AS. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia. 1996;39(8):940-5. (Pubitemid 26249113)
8. Spray BJ, Atassi NG, Tuttle AB, Freedman BI. Familial risk, age at onset, and cause of end-stage renal disease in white Americans. J Am Soc Nephrol. 1995;5(10):1806-10.
9. O'Dea DF, Murphy SW, Hefferton D, Parfrey PS. Higher risk for renal failure in first-degree relatives of white patients with endstage renal disease: A population-based study. Am J Kidney Dis. 1998;32(5):794-801. (Pubitemid 28516310)
10. Forsblom CM, Kanninen T, Lehtovirta M, Saloranta C, Groop LC. Heritability of albumin excretion rate in families of patients with Type II diabetes. Diabetologia. 1999;42(11):1359-66. (Pubitemid 29500974)
11. Ramirez SP, McClellan W, Port FK, Hsu SI. Risk factors for proteinuria in a large, multiracial, Southeast Asian population. J Am Soc Nephrol. 2002;13(7):1907-17. (Pubitemid 34700617)
12. Canani LH, Gerchman F, Gross JL. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes. 1999;48(4):909-13. (Pubitemid 29153094)
13. Vijay V, Snehalatha C, Shina K, Lalitha S, Ramachandran A. Familial aggregation of diabetic kidney disease in Type 2 diabetes in south India. Diabetes Res Clin Pract. 1999;43(3):167-71. (Pubitemid 29202126)
14. Maeda S, Osawa N, Hayashi T, Tsukada S, Kobayashi M, Kikkawa R. Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population. Kidney Int Suppl. 2007;106:S43-8. (Pubitemid 47172560)
15. Freedman BI, Soucie JM, McClellan WM. Family history of endstage renal disease among incident dialysis patients. J Am Soc Nephrol. 1997;8(12):1942-5. (Pubitemid 28185453)
16. Freedman BI, Tuttle AB, Spray BJ. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1995;25(5):710-3.
17. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1990;33(7):438-43. (Pubitemid 20220945)
18. Nelson RG, Newman JM, Knowler WC, Sievers ML, Kunzelman CL, Pettitt DJ, et al. Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia. 1988;31(10):730-6.
19. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: Practical considerations. Nat Rev Genet. 2002;3(5):391-7. (Pubitemid 34506720)
20. Ma RC, Tam CH, Wang Y, Luk AO, Hu C, Yang X, et al. Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA. 2010;304(8):881-9.
21. Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A. 2008;105 (19):6998-7003. (Pubitemid 351754519)
22. Liu Y, Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Rich SS, et al. T-786 C polymorphism of the endothelial nitric oxide synthase gene is associated with albuminuria in the diabetes heart study. J Am Soc Nephrol. 2005;16(4):1085-90. (Pubitemid 41710319)
23. Nagase S, Suzuki H, Wang Y, Kikuchi S, Hirayama A, Ueda A, et al. Association of ecNOS gene polymorphisms with end stage renal diseases. Mol Cell Biochem. 2003;244(1-2):113-8. (Pubitemid 36411061)
24. Noiri E, Satoh H, Taguchi J, Brodsky SV, Nakao A, Ogawa Y, et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension. 2002;40(4):535-40.
25. Suzuki H, Nagase S, Kikuchi S, Wang Y, Koyama A. Association of a missense Glu298Asp mutation of the endothelial nitric oxide synthase gene with end stage renal disease. Clin Chem. 2000;46 (11):1858-60.
26. Wang F, Fang Q, Yu N, Zhao D, Zhang Y, Wang J et al. Association between genetic polymorphism of the angiotensinconverting enzyme and diabetic nephropathy: A meta-analysis comprising 26,580 subjects. J Renin Angiotensin Aldosterone Syst. 2011; ePub. PMID 21810896. Large-scale meta-analysis of the angiotensin-converting exzyme (ACE) insertion/deletion (I/D) polymorphism showing striking association in Asians with type 2 diabetes.
27. Mooyaart AL, Valk EJ, van Es LA, Bruijn JA, de Heer E, Freedman BI et al. Genetic associations in diabetic nephropathy: A meta-analysis. Diabetologia.54(3):544-53. Bioinformatic metaanalysis of cited associations associations with DN identifying 24 genetic variants associated with disease.
28. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes. 1998;47(5):821-30. (Pubitemid 28201814)
29. Vardarli I, Baier LJ, Hanson RL, Akkoyun I, Fischer C, Rohmeiss P, et al. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int. 2002;62(6):2176-83. (Pubitemid 35366173)
30. Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C, et al. Carnosine as a protective factor in diabetic nephropathy: Association with a leucine repeat of the carnosinase gene CNDP1. Diabetes. 2005;54(8):2320-7. (Pubitemid 41134258)
31. Freedman BI, Hicks PJ, Sale MM, Pierson ED, Langefeld CD, Rich SS, et al. A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrol Dial Transplant. 2007;22(4):1131-5. (Pubitemid 46523428)
32. Ahluwalia TS, Lindholm E, Groop LC. Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes. Diabetologia.54(9):2295-302. Evaluation of positional candidate genes (CNDP1 and CNDP2) implicating common variants in DN.
33. Knowler WC, Coresh J, Elston RC, Freedman BI, Iyengar SK, Kimmel PL, et al. The Family Investigation of Nephropathy and Diabetes (FIND): Design and methods. J Diabetes Complications. 2005;19(1):1-9. (Pubitemid 40092364)
34. Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH, et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: The family investigation of nephropathy and diabetes (FIND). Diabetes. 2007;56(6):1577-85. (Pubitemid 46842614)
35. Schelling JR, Abboud HE, Nicholas SB, Pahl MV, Sedor JR, Adler SG, et al. Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: The Family Investigation of Nephropathy and Diabetes (FIND). Diabetes. 2008;57(1):235-43.
36. Osterholm AM, He B, Pitkaniemi J, Albinsson L, Berg T, Sarti C, et al. Genome-wide scan for type 1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a single locus on chromosome 3q. Kidney Int. 2007;71(2):140-5. (Pubitemid 46094687)
37. He B, Osterholm AM, Hoverfalt A, Forsblom C, Hjorleifsdottir EE, Nilsson AS, et al. Association of genetic variants at 3q22 with nephropathy in patients with type 1 diabetes mellitus. Am J Hum Genet. 2009;84(1):5-13.
38. Vionnet N, Tregouet D, Kazeem G, Gut I, Groop PH, Tarnow L, et al. Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: Strongest evidence for association with a variant in the promoter region of the adiponectin gene. Diabetes. 2006;55(11):3166-74. (Pubitemid 44923657)
39. Igo RP, Jr., Iyengar SK, Nicholas SB, Goddard KA, Langefeld CD, Hanson RL et al. Genomewide linkage scan for diabetic renal failure and albuminuria: The FIND study. Am J Nephrol.33(5):381-9. Multiethnic linkage study of DN and associated quantitative traits in patients with type 1 and type 2 diabetes stengthens the evidence of linkage for previously identfied regions and implicates novel loci.
40. Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol. 2010;21(9):1422-6.
41. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329 (5993):841-5. Ethnic-specific variants in APOL1 are associated with nephropathy, harbor signatures of natural selection and are functionally validated.
42. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128(3):345-50.
43. Rao M, Mottl AK, Cole SA, Umans JG, Freedman BI, Bowden DW et al. Meta-analysis of genome-wide linkage scans for renal function traits. Nephrol Dial Transplant. 2012;27(2):647-56. Utilization of genome scan meta-analysis in DN to sythesize results from surrogate measures.
44. Wise LH, Lanchbury JS, Lewis CM. Meta-analysis of genome searches. Ann Hum Genet. 1999;63(Pt 3):263-72. (Pubitemid 29471969)
45. Zintzaras E, Ioannidis JP. HEGESMA: Genome search metaanalysis and heterogeneity testing. Bioinformatics. 2005;21 (18):3672-3. (Pubitemid 41264106)
46. Zintzaras E, Ioannidis JP. Heterogeneity testing in metaanalysis of genome searches. Genet Epidemiol. 2005;28 (2):123-37.
47. Trikalinos TA, Karvouni A, Zintzaras E, Ylisaukko-oja T, Peltonen L, Jarvela I, et al. A heterogeneity-based genome search metaanalysis for autism-spectrum disorders. Mol Psychiatry. 2006;11 (1):29-36. (Pubitemid 43251085)
48. Zintzaras E, Kitsios G. Identification of chromosomal regions linked to premature myocardial infarction: A meta-analysis of whole-genome searches. J Hum Genet. 2006;51(11):1015-21. (Pubitemid 44800748)
49. Zintzaras E, Kitsios G, Harrison GA, Laivuori H, Kivinen K, Kere J, et al. Heterogeneity-based genome search meta-analysis for preeclampsia. Hum Genet. 2006;120(3):360-70. (Pubitemid 44400470)
50. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273(5281):1516-7. (Pubitemid 26301653)
51. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009;5(6):e1000529.
52. The International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789-96.
53. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164):851-61. (Pubitemid 47598626)
54. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest. 2008;118(5):1590-605. (Pubitemid 351632361)
55. Manolio TA, Collins FS. The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med. 2009;60:443-56.
56. Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, et al. Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes. 2005;54(4):1171-8. (Pubitemid 40446333)
57. Leak TS, Perlegas PS, Smith SG, Keene KL, Hicks PJ, Langefeld CD, et al. Variants in intron 13 of the ELMO1 gene are associated with diabetic nephropathy in African Americans. Ann Hum Genet. 2009;73(2):152-9.
58. Pezzolesi MG, Katavetin P, Kure M, Poznik GD, Skupien J, Mychaleckyj JC, et al. Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy. Diabetes. 2009;58(11):2698-702.
59. Kamiyama M, Kobayashi M, Araki S, Iida A, Tsunoda T, Kawai K, et al. Polymorphisms in the 3' UTR in the neurocalcin delta gene affect mRNA stability, and confer susceptibility to diabetic nephropathy. Hum Genet. 2007;122(3-4):397-407. (Pubitemid 47616548)
60. Maeda S, Kobayashi MA, Araki S, Babazono T, Freedman BI, Bostrom MA, et al. A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet. 2010;6(2): E1000842.
61. Tang SC, Leung VT, Chan LY, Wong SS, Chu DW, Leung JC, et al. The acetyl-coenzyme A carboxylase beta (ACACB) gene is associated with nephropathy in Chinese patients with type 2 diabetes. Nephrol Dial Transplant. 2010;25(12):3931-4.
62. Hanson RL, Craig DW, Millis MP, Yeatts KA, Kobes S, Pearson JV, et al. Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genomewide single nucleotide polymorphism association study. Diabetes. 2007;56(4):975-83. (Pubitemid 46525073)
63. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes. 2009;58(6):1403-10.
64. Freedman BI, Langefeld CD, Lu L, Divers J, Comeau ME, Kopp JB, et al. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet. 2011;7(6):e1002150.
65. McDonough CW, Palmer ND, Hicks PJ, Roh BH, An SS, Cooke JN et al. A genome-wide association study for diabetic nephropathy genes in African Americans. Kidney Int.79(5):563-72. The first GWAS for DN in the African American population.
66. Gitter J, Langefeld CD, Rich SS, Pedley CF, Bowden DW, Freedman BI. Prevalence of nephropathy in black patients with type 2 diabetes mellitus. Am J Nephrol. 2002;22(1):35-41. (Pubitemid 34264184)
67. Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A, et al. A high-density admixture map for disease gene discovery in African Americans. Am J Hum Genet. 2004;74 (5):1001-13. (Pubitemid 38568970)
68. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008;40(10):1185-92.
69. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40(10):1175-84.
70. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22 (11):2129-37.
71. Pattaro C, Aulchenko YS, Isaacs A, Vitart V, Hayward C, Franklin CS, et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int. 2009;76(3):297-306.
72. O'Seaghdha CM, Parekh RS, Hwang SJ, Li M, Kottgen A, Coresh J, et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet. 2011;20(12):2450-6.
73. Cooke JN, Bostrom MA, Hicks PJ, Ng MC, Hellwege JN, Comeau ME et al. Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant. 2012;27(4):1505-11
74. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol. 2011;22(11):2098-105.
75. Freedman BI, Langefeld CD, Turner J, Nunez M, High KP, Spainhour M et al. APOL1 associations with mild kidney disease in African American first-degree relatives of patients with non-diabetic ESRD. Kidney International. 2012, in press.
76. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747-53.
77. McClellan J, King MC. Genetic heterogeneity in human disease. Cell. 2010;141(2):210-7.
78. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet. 2007;8(4):253-62. (Pubitemid 46439287)
79. Dwivedi RS, Herman JG, McCaffrey TA, Raj DS. Beyond genetics: Epigenetic code in chronic kidney disease. Kidney Int. 2011;79 (1):23-32.
80. Sapienza C, Lee J, Powell J, Erinle O, Yafai F, Reichert J et al. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics. 2011;6(1):20-8. Early studies of DNA methylation profiling in DN demonstrating utility of approach.